Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and ...

Patent covers brilaroxazine use for treating Pulmonary Fibrosis-Similar patents have also been granted in key markets around the world ...

Endeavor BioMedicines ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational benefits to patients with life-threatening diseases, ...

An announcement from Vicore Pharma Holding AB ( ($SE:VICO) ) is now available. Vicore Pharma Holding AB announced a directed share issue to raise ...

Nerandomilast is an oral, preferential inhibitor of PDE4B approved for the treatment of IPF in adult patients. Nerandomilast was approved by the U.S. Food and Drug Administration (FDA) after securing ...

An update from Vicore Pharma Holding AB ( ($SE:VICO) ) is now available. Vicore Pharma Holding AB has successfully raised approximately USD 48 ...

Angiotensin-converting enzyme (ACE) inhibitor therapy may reduce all-cause mortality in idiopathic pulmonary fibrosis (IPF) but not in COPD.

Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...

Detailed price information for Cumberland Pharmaceu (CPIX-Q) from The Globe and Mail including charting and trades.

Melbourne-based RAGE Biotech has raised $29 million in Series A to take its treatment for chronic lung disease into ...

Each year, the European Lung Foundation (ELF) recognises outstanding research that advances patient-centred care and promotes ...

The investigators also reported that LTI-03 helped preserve alveolar epithelial type II (AT2) progenitor cells, which are essential for lung repair and regeneration. Current IPF therapies primarily ...